BioNTech at $90 while its oncology AI narrative points to a fair value of $499

By Simply Wall St · June 26, 2026.

BioNTech (NasdaqGS: BNTX) is trading around $90 per share at a time when its stock-market performance reflects contradictory signals. Over the past 30 days, the stock has fallen 2.44%; over the past 90 days it has risen 5.04%; and over the past year it is down roughly 15%. The most striking figure, however, is the total return over five years: a 59.43% loss for long-term shareholders, which underscores that the momentum generated during the COVID-19 pandemic —when the company co-developed its mRNA COVID-19 vaccine with Pfizer— has almost entirely dissipated.

**The most-followed narrative: fair value of $499.94**

The most popular narrative about BNTX on Simply Wall St's community platform is a thesis that pegs the company's fair value at $499.94 per share, which would imply that the market is undervaluing it by roughly 82%. This estimate rests on three pillars: aggressive revenue expansion, high profit margins, and a forward earnings multiple comparable to that of high-growth companies.

The thread running through that narrative is explicitly AI applied to oncology. The text cited in the article compares today's cancer treatments —surgery, chemotherapy and radiotherapy— with methods that by 2050 could look as archaic as those of the 1960s or 1970s. The quote refers directly to Uğur Şahin, BioNTech's co-founder and CEO, describing him as someone with an exceptional capacity for pattern recognition and complexity reduction, and suggests that his choice to fight cancer rather than found a conventional tech company is a stroke of luck for humanity. The premise: medicine, AI, robotics and the decoding of human metabolism into algorithms are converging toward a fundamental transformation of oncology.

**The flip side: the price-to-sales ratio doesn't keep pace**

Against that optimistic view, the article itself offers an alternative reading based on current valuation multiples. BioNTech's price-to-sales (P/S) ratio stands at 7.1 times, above the ratio considered fair (5x) and also above the average of its direct peer group (6.2x). It only sits below the median for the U.S. biotech industry as a whole (11.1x).

This divergence poses a clear dilemma for any investor: should they give more weight to the qualitative narrative about AI's transformative potential in oncology, or to what current sales multiples suggest about the stock's relative price? If growth or profitability fall short of the most optimistic expectations, the valuation risk is real.

**Specific risks identified**

The article also points to the main risk vectors for the bullish thesis. The first: that the key oncology clinical trials deliver disappointing results. BioNTech has an active pipeline of mRNA-based and immunotherapy cancer candidates, but the path of oncology research is riddled with failures even for the most technologically well-positioned companies. The second risk: that AI-assisted drug design fails to translate into commercially viable therapies within the timeframes the market is pricing in.

Overall, the AI-driven drug-discovery sector —which includes companies such as Recursion Pharmaceuticals, Exscientia and Insilico Medicine— has spent years promising to dramatically accelerate development cycles, but the success rate in late-stage clinical trials remains a bottleneck that AI has yet to resolve systematically.

**BioNTech's context as an AI player in healthcare**

BioNTech is not solely the COVID vaccine company. In recent years it has built a diversified technology platform that includes therapeutic mRNA for cancer, adoptive cell therapies (CAR-T), bispecific antibodies and immunomodulators. The company has announced collaborations with AI firms and has invested in its own computational capabilities to accelerate the design of personalized neoantigens —the approach behind so-called individualized cancer vaccines—, an area where deep-learning models play a growing role in predicting which of each patient's tumor mutations will generate an effective immune response.

In addition, BioNTech maintains a solid financial position with a sizable cash pile inherited from COVID vaccine revenues, giving it a long runway to fund its R&D without needing to dilute shareholders in the short term. According to the article's own profile, the company stands out for an excellent balance sheet, a trait that nuances the debate between undervaluation and overvaluation.

**Implications for AI and healthcare investors**

The article mentions that there are currently 39 AI healthcare stocks that investors interested in the sector could analyze, without identifying them by name. As sector context, the convergence of generative AI, computational biology and mRNA platforms represents one of the most active investment fronts in venture capital and public markets during 2025-2026. The major pharmaceutical companies —Roche, Novartis, AstraZeneca— have signed multibillion-dollar deals with AI startups for drug discovery, which validates the direction of the thesis even if it does not guarantee the results.

**Overall perspective**

In short, Simply Wall St does not take sides: it presents the majority narrative of extreme undervaluation alongside the warning signal emitted by the P/S ratio. The tension between the two readings neatly sums up BioNTech's dilemma: a company with potentially disruptive technology, a healthy balance sheet and a powerful AI oncology narrative, but whose market price already incorporates a degree of optimism according to sales multiples, and whose recent stock-market track record —especially over five years— invites caution. The final verdict will depend on whether the clinical data from its oncology pipeline and its ability to monetize AI back the most ambitious projections.